PDMR Notification RSU Vesting

RNS Number : 3711T

PureTech Health PLC

22 July 2022

 

22 July 2022

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 21 July 2021 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 15 June 2022 immediately prior to the Company's Annual General Meeting of Stockholders . Each PDMR received vested ordinary shares on 22 July 2022.

The Company's total issued ordinary share capital is 288,689,450 shares after the share issuance to the PDMRs, 3,563,665 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Raju Kucherlapati John LaMattina Robert Langer Kiran Mazumdar-Shaw Marjorie Scardino Christopher Viehbacher
2	Reason for the notification
a)	Position/status	Non-Executive Directors
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan.
c)	Price(s) and volume(s)	Recipient Price Amount Raju Kucherlapati 0.01 GBP 11,190 ordinary shares John LaMattina 0.01 GBP 11,190 ordinary shares Robert Langer 0.01 GBP 11,190 ordinary shares Kiran Mazumdar-Shaw 0.01 GBP 11,190 ordinary shares Marjorie Scardino 0.01 GBP 11,190 ordinary shares Christopher Viehbacher 0.01 GBP 11,190 ordinary shares
d)	Aggregated information - Aggregated volume - Price	Price Aggregate Volume 0.01 GBP 67,140 ordinary shares
e)	Date of the transaction	22 July 2022
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

 

END

 

 

DSHPPUMPMUPPGBG